Jaana Suvisaari

Prof. Dr. Jaana Suvisaari

Finnish Institute for Health and Welfare, 00271 Helsinki, Finland
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2008 in Nature
Verified
Journal Article
Closed access
PDF file
GRGROUP
GROUP
HSHreinn Stefansson
Hreinn Stefansson
DRDan Rujescu
Dan Rujescu
SCSven Cichon
Sven Cichon
OPOlli P. H. Pietiläinen
Olli P. H. Pietiläinen
KSKari Stefansson
Kari Stefansson

1 July 2009 in Nature
Verified
Journal Article
Closed access
PDF file
†(†Genetic Risk and Outcome in Psychosis (GROUP)
†Genetic Risk and Outcome in Psychosis (GROUP)
HSHreinn Stefansson
Hreinn Stefansson
RORoel A. Ophoff
Roel A. Ophoff
SSStacy Steinberg
Stacy Steinberg
OAOle A. Andreassen
Ole A. Andreassen
DCDavid A. Collier
David A. Collier

25 August 2013 in Nature Genetics
Verified
Journal Article
Open access
PDF file
SRStephan Ripke
Stephan Ripke
COColm O'Dushlaine
Colm O'Dushlaine
KCKimberly Chambert
Kimberly Chambert
JMJennifer L Moran
Jennifer L Moran
AKAnna K Kähler
Anna K Kähler
PSPatrick F Sullivan
Patrick F Sullivan
Patrick Sullivan and colleagues report a multi-stage genome-wide association study for schizophrenia in a Swedish population. They identify 13 loci newly associated with schizophrenia. Schizophrenia is an idiopathic mental disorder with a heritable component and a substantial public health impact. We conducted a multi-stage genome-wide association study (GWAS) for schizophrenia beginning with a Swedish national sample (5,001 cases and 6,243 controls) followed by meta-analysis with previous schizophrenia GWAS (8,832 cases and 12,067 controls) and finally by replication of SNPs in 168 genomic regions in independent samples (7,413 cases, 19,762 controls and 581 parent-offspring trios). We identified 22 loci associated at genome-wide significance; 13 of these are new, and 1 was previously implicated in bipolar disorder. Examination of candidate genes at these loci suggests the involvement of neuronal calcium signaling. We estimate that 8,300 independent, mostly common SNPs (95% credible interval of 6,300–10,200 SNPs) contribute to risk for schizophrenia and that these collectively account for at least 32% of the variance in liability. Common genetic variation has an important role in the etiology of schizophrenia, and larger studies will allow more detailed understanding of this disorder.

1 October 2015 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
BVBjarni J. Vilhjálmsson
Bjarni J. Vilhjálmsson
JYJian Yang
Jian Yang
HFHilary K. Finucane
Hilary K. Finucane
AGAlexander Gusev
Alexander Gusev
SLSara Lindström
Sara Lindström
WZWei Zheng
Wei Zheng

1 January 2007 in Archives of General Psychiatry
Verified
Journal Article
Closed access
PDF file
JPJonna Perälä
Jonna Perälä
Jaana SuvisaariJaana Suvisaari
Jaana Suvisaari
SSSamuli I. Saarni
Samuli I. Saarni
KKKimmo Kuoppasalmi
Kimmo Kuoppasalmi
EIErkki Isometsä
Erkki Isometsä
JLJouko Lönnqvist
Jouko Lönnqvist
Research from JAMA Psychiatry — Lifetime Prevalence of Psychotic and Bipolar I Disorders in a General Population

14 September 2015 in Nature
Verified
Journal Article
Open access
PDF file
TCThe UK10K Consortium
The UK10K Consortium
WGWriting group
Writing group
KWKlaudia Walter
Klaudia Walter
JMJosine L. Min
Josine L. Min
JHJie Huang
Jie Huang
WZWeihua Zhang
Weihua Zhang
The contribution of rare and low-frequency variants to human traits is largely unexplored. Here we describe insights from sequencing whole genomes (low read depth, 7×) or exomes (high read depth, 80×) of nearly 10,000 individuals from population-based and disease collections. In extensively phenotyped cohorts we characterize over 24 million novel sequence variants, generate a highly accurate imputation reference panel and identify novel alleles associated with levels of triglycerides (APOB), adiponectin (ADIPOQ) and low-density lipoprotein cholesterol (LDLR and RGAG1) from single-marker and rare variant aggregation tests. We describe population structure and functional annotation of rare and low-frequency variants, use the data to estimate the benefits of sequencing for association studies, and summarize lessons from disease-specific collections. Finally, we make available an extensive resource, including individual-level genetic and phenotypic data and web-based tools to facilitate the exploration of association results.